camptothecin has been researched along with carbostyril in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 5 (45.45) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, DT; Clement, JJ; Permana, PA; Plattner, JJ; Shen, LL; Snapka, RM | 1 |
| Beard, C; Bronson, R; Buhlmann, JE; Curry, R; Dausman, J; Guarente, L; Jaenisch, R; Johnson, B; Lipman, R; Lombard, DB; Marciniak, RA; Sharpe, A | 1 |
| Heinemann, V | 1 |
| Alpaugh, RK; Cohen, SJ; Gallo, J; Gentner, L; Lewis, NL; Meropol, NJ; Palmer, PA; Rogatko, A; Schol, J; Verhaeghe, T; Weiner, LM; Yeslow, G; Zannikos, P | 1 |
| de Bruijn, P; de Heus, G; de Jonge, MJ; Eskens, FA; Kehrer, DF; Klaren, A; Mathijssen, RH; Palmer, PA; Planting, AS; Sparreboom, A; Verhaeghe, T; Verheij, C; Verweij, J; Xie, R; Zhang, S | 1 |
| Borner, MM | 1 |
| Leo, E; Marchand, C; Pommier, Y; Zhang, H | 1 |
| Agama, K; An, LK; Du, J; Gu, LQ; Huang, ZS; Li, D; Pommier, Y; Wu, N; Wu, XW | 1 |
| Peyroche, A; Tallec, BL | 1 |
| Ban, LY; Fang, FQ; Guo, HS; Liu, JW; Yu, PY; Zhang, J | 1 |
| Caron, NS; Deng, Y; Ehrnhoefer, DE; Hayden, MR; Qiu, X; Tsang, M | 1 |
3 review(s) available for camptothecin and carbostyril
| Article | Year |
|---|---|
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
DNA topoisomerases and their poisoning by anticancer and antibacterial drugs.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Camptothecin; DNA Topoisomerases; Doxorubicin; Enzyme Inhibitors; Etoposide; Humans; Mitoxantrone; Quinolones; Topoisomerase Inhibitors | 2010 |
2 trial(s) available for camptothecin and carbostyril
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of the farnesyltransferase inhibitor R115777 in combination with irinotecan in patients with advanced cancer.
Topics: Administration, Oral; Aged; Alkyl and Aryl Transferases; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasms; Quinolones | 2004 |
Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinolones; Treatment Outcome | 2004 |
6 other study(ies) available for camptothecin and carbostyril
| Article | Year |
|---|---|
Quinobenoxazines: a class of novel antitumor quinolones and potent mammalian DNA topoisomerase II catalytic inhibitors.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cattle; Cell Line; Chlorocebus aethiops; DNA Replication; Doxorubicin; Kidney; Kinetics; Oxazines; Quinolones; Simian virus 40; Structure-Activity Relationship; Teniposide; Thymus Gland; Topoisomerase II Inhibitors | 1994 |
Mutations in the WRN gene in mice accelerate mortality in a p53-null background.
Topics: 4-Nitroquinoline-1-oxide; Animals; Blotting, Western; Camptothecin; Cell Division; Cells, Cultured; Cellular Senescence; Cloning, Molecular; DNA Helicases; Dose-Response Relationship, Drug; Embryo, Mammalian; Exodeoxyribonucleases; Fibroblasts; Gene Library; Life Expectancy; Mice; Mice, Knockout; Molecular Sequence Data; Mutation; Phenotype; Quinolones; RecQ Helicases; Spleen; Time Factors; Tissue Distribution; Tumor Suppressor Protein p53; Werner Syndrome Helicase | 2000 |
A novel DNA topoisomerase I inhibitor with different mechanism from camptothecin induces G2/M phase cell cycle arrest to K562 cells.
Topics: Camptothecin; Cell Division; Cell Proliferation; DNA Topoisomerases, Type I; Humans; Indolizines; K562 Cells; Quinolones; Topoisomerase I Inhibitors | 2010 |
Using DNA damage sensitivity phenotypes to characterize mutations affecting proteasome function.
Topics: 4-Nitroquinoline-1-oxide; Camptothecin; Canavanine; DNA Damage; Methyl Methanesulfonate; Mutation; Polyubiquitin; Proteasome Endopeptidase Complex; Quinolones; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2012 |
Anti-cancer effects of 2-oxoquinoline derivatives on the HCT116 and LoVo human colon cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Cell Line, Tumor; Colonic Neoplasms; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; HCT116 Cells; Humans; Irinotecan; JNK Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Quinolones | 2015 |
Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons.
Topics: Animals; Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Camptothecin; Caspase 6; Cerebral Cortex; COS Cells; Disease Models, Animal; Dose-Response Relationship, Drug; Down Syndrome; Gene Expression Regulation; Humans; Huntingtin Protein; Mice; Mice, Transgenic; Mutation; Neurons; Protein Synthesis Inhibitors; Quinolones; Time Factors; Tosylphenylalanyl Chloromethyl Ketone | 2016 |